NCT01840566View on ClinicalTrials.gov

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Carmustine

DRUG

Etoposide

DRUG

Cytarabine

DRUG

Melphalan

BIOLOGICAL

Pegfilgrastim

BIOLOGICAL

19-28z T CELLS

PROCEDURE

Autologous Stem Cell Transplantation

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activites), Rockville Centre

11725

Memorial Sloan Kettering Commack (Limited protocol activities), Commack

07920

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01840566 - High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter